April 2026 Boston Scientific Corporation expanded its cardiac electrophysiology portfolio by launching upgraded FARAPULSE™ Pulsed Field Ablation (PFA) System capabilities with enhanced mapping and workflow integration features. The expansion supports broader adoption of non-thermal ablation technologies for atrial fibrillation treatment.
February 2026 Medtronic plc launched expanded configurations of its PulseSelect™ Pulsed Field Ablation System following regulatory clearances in additional markets. The product expansion strengthens Medtronic’s electrophysiology portfolio by providing physicians with advanced tools for treating cardiac arrhythmias.
October 2025 Johnson & Johnson MedTech (Biosense Webster) received additional regulatory approvals for its VARIPULSE™ Pulsed Field Ablation Platform, expanding availability of its next-generation cardiac ablation technology. The platform combines pulsed field energy delivery with advanced mapping capabilities for atrial fibrillation procedures.
June 2025 Abbott Laboratories expanded its electrophysiology product portfolio with the launch of enhanced TactiFlex™ Sensor Enabled™ Ablation Catheter capabilities in additional markets. The technology improves catheter contact sensing and lesion formation control during cardiac ablation procedures.